Aimmune Therapeutics Competitors, Revenue, Alternatives and Pricing
Overview
City Ranking
Industry Ranking
Growjo 10k Ranking
Estimated Revenue & Financials
- Aimmune Therapeutics's estimated annual revenue is currently $30.7M per year.
- Aimmune Therapeutics received $170.0M in venture funding in January 2019.
- Aimmune Therapeutics's estimated revenue per employee is $81,622
- Aimmune Therapeutics's total funding is $540M.
Employee Data
- Aimmune Therapeutics has 376 Employees.
- Aimmune Therapeutics grew their employee count by 19% last year.
- Aimmune Therapeutics currently has 13 job openings.
Aimmune Therapeutics Competitors
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
| $7M | 45 | 10% | N/A | - | N/A | |
| N/A | 205 | N/A | N/A | - | N/A | |
| $46.8M | 302 | 4% | N/A | - | N/A | |
| $22.3M | 144 | N/A | N/A | - | N/A | |
| $44.3M | 286 | N/A | N/A | - | N/A | |
| $101.2M | 653 | 46% | N/A | - | N/A | |
| $33.3M | 215 | 3% | N/A | - | N/A | |
| $28.7M | 185 | 8% | N/A | - | N/A | |
| $39.4M | 254 | N/A | N/A | - | N/A | |
| $6.5M | 42 | 14% | N/A | - | N/A |
What Is Aimmune Therapeutics?
Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy. Aimmune is located in Brisbane, California - the heart of San Francisco's biotechnology hub - with additional offices in the Kings Cross area of London and in Raleigh, North Carolina.
keywords:Biotechnology,Food & Beverages,Healthcare,Pharmaceuticals376
Number of Employees
$30.7M
Revenue (est)
13
Current Jobs
19%
Employee Growth %
$540M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Aimmune Therapeutics News
13, will be a pivotal moment for Aimmune Therapeutics (AIMT 5), the biopharma company that developed the new treatment, called AR101.
BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food ...
Operator. Good afternoon, ladies and gentlemen, and welcome to the Aimmune Therapeutics, Second Quarter 2019 Earnings Conference Call.
Aimmune Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-11-07 | $145.0M | Nestlé Health Scienc | Nestlé Health Science | Article |
| 2018-02-21 | $177.5M | Undisclosed | Article | |
| 2018-11-29 | $98.0M | Undisclosed | Nestlé Health Science | Article |
| 2019-01-07 | $170.0M | Undisclosed | KKR | Article |
Aimmune Therapeutics Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2015-10-12 | Howard Raff | Consultant | Article |
| 2016-04-06 | Douglas Sheehy | General Counsel/Secretary | Article |
| 2016-06-22 | Daniel Adelman | Chief Medical Officer | Article |
| 2017-04-14 | Eric Bjerkholt | Chief Financial Officer | Article |
| 2018-06-12 | Jayson Dallas | President and Chief Executive Officer | Article |
| 2019-01-21 | Andrew Oxtoby | Chief Commercial Officer | Article |